Biotech · Private company · San Mateo, CA, US
Revagenix, Inc.
Track this companyFree. Adds Revagenix, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- Rev-56 for InhalationPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. AeruginosaPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 13, 2026ClinicalTrials.gov NCT07709494 · fetched Nov 12, 2026
NIH awards4
- Development of Therapeutic Products for Antibiotic Resistant BacteriaFiscal year 2026 · $2.1MNIH RePORTER 75N93020C00018-P00021-9999-1 · fetched Nov 12, 2026
- Development of Therapeutic Products for Antimicrobial Resistant (AMR) Infections and Emerging Infectious DiseasesFiscal year 2026 · $12.1MNIH RePORTER 75N93022C00061-P00008-9999-1 · fetched Nov 12, 2026
- Development of Therapeutic Products for Antibiotic Resistant BacteriaFiscal year 2024 · $6.6MNIH RePORTER 75N93020C00018-P00014-9999-1 · fetched Nov 12, 2026
- Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious DiseasesFiscal year 2024 · $11.3MNIH RePORTER 75N93022C00061-P00002-9999-1 · fetched Nov 12, 2026